Update zur juvenilen systemischen Sklerodermie

I. Foeldvari

doi:10.1055/s-0037-1618172

Arthritis und Rheuma, Table of Contents

Arthritis und Rheuma 2013; 33(02): 114-117
DOI: 10.1055/s-0037-1618172

Kinderrheumatologie: Übersichtsarbeit

Schattauer GmbH

Update zur juvenilen systemischen Sklerodermie

Juvenile systemic sclerosis – update

I. Foeldvari

¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Kompetenz-Zentrum für Sklerodermie und Uveitis im Kindes- und Jugendalter, An der Schön Klinik Hamburg Eilbek, Hamburg

› Author Affiliations

Abstract

Zusammenfassung

Die juvenile systemische Sklerodermie (jSSc) ist eine „Orphan“-Erkrankung mit einer Inzidenz von 0,27 bis 0,5 pro eine Million Kinder. Bei bis zu 90 Prozent der Patienten ist ein diffuser Verlauf zu beobachten, dennoch ist die Überlebensrate besser als bei erwachsenen Patienten. Bei langfristigem Verlauf sinkt der Anteil der Patienten mit diffuser Sklerodermie auf 40 Prozent. Die Overlap-Symptomatik scheint einen Überlebensvorteil zu bieten. Die meisten SSc-spezifischen Erfassungsmethoden sind bei der jSSc nicht validiert. Die Therapie beruht auf Erfahrungen aus der Erwachsenenmedizin.

Summary

Juvenile systemic sclerosis is an orphan disease with an incidence of 0.27 to 0.5 in a million children. In up to 90 % of the patients a diffuse course of disease can be noticed. However, the survival rate is higher than in adult patients. In the long-term course the part of patients with a diffuse form of sclerosis decreases to 40 %. The „overlap“ symptomatology seems to offer a survival benefit. Most of the detection methods specific for sclerosis are not validated for the juvenile systemic sclerosis. Therapy is based on the experiences made in adult medicine.

Schlüsselwörter

Juvenile systemische Sklerodermie - Orphan-Erkrankung

Keywords

Juvenile systemic sclerosis - orphan disease

Full Text

References

Literatur
1 Zulian F. et al. The Pediatric Rheumatology European Society/American College of Rheumatology/ European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007; 57 (02) 203-212.
2 Masi AT. et al. Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma). Arthritis Rheum 1980; 23 (05) 581-590.
3 LeRoy EC. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
4 Foeldvari I. et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 2000; 39 (05) 556-559.
5 Pelkonen PM. et al. Incidence of systemic connective tissue disease in children: a nationwide prospective study in Finland. J Rheumatol 1994; 21: 2143-2146.
6 Herrick AL. et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken) 2010; 62 (02) 213-218.
7 Abraham DJ. et al. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl. 03) iii3-iii7.
8 Jimenez SA, Artlett CM. Microchimerism and systemic sclerosis. Curr Opin Rheumatol 2004; 17: 86-90.
9 Romano E. et al. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011; 29 (02) (Suppl. 65) S75-S86.
10 Martini G. et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 2006; 54 (12) 3971-3978.
11 Foeldvari I. Update on pediatric systemic sclerosis: similarities and differences from adult disease. Curr Opin Rheumatol 2008; 20 (05) 608-612.
12 Sulli A. et al. Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 2012; 64 (03) 821-825.
13 Herrick ML. et al. The influence of age on nailfold capillary dimension in childhood. J Rheumatol 2000; 27: 797-800.
14 Dolezalova P. et al. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 2003; 62: 444-449.
15 Avouac J. et al. Articular involvement in systemic sclerosis. Rheumatology (Oxford) 2012; 51 (08) 1347-1356.
16 Desai CS. et al. Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol 2011; 23 (06) 545-554.
17 Rodnan GP. et al. Skin thickness and collagen content in progressive systemic sclerosis and localised scleroderma. Arthritis Rheum 1979; 22: 130-140.
18 Foeldvari I, Wierk A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology (Oxford) 2006; 45 (01) 76-78.
19 Lammers AE. et al. The 6-minute walk test: normal values for children of 4–11 years of age. Arch Dis Child 2008; 93 (06) 464-468.
20 Li AM, Yin J, Yu CCW. et al. The six-minute walk test in healthy children: reliability and validity. Eur Respir J 2005; 25: 1057-1060.
21 Li AM, Yin J, Au JT. et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med 2007; 176 (02) 174-180.
22 Medsger TA. et al. A disease severity scale for systemic sclerosis development and testing. J Rheumatol 1999; 26: 2159-2167.
23 Kowal-Bielecka O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68 (05) 620-628.
24 Martini G. et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford) 2009; 48: 119-122.
25 Foeldvari I. et al. Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort. J Rheumatol 2010; 37 (11) 2422-2426.
26 Foeldvari I. et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. Rheumatology (Oxford) 2012; 51: 1832-1837.